Acta Med. 2015, 58: 25-31

https://doi.org/10.14712/18059694.2015.88

Increase of Intracellular BAFF in B Cells of Sjögren’s Patients Is Not Affected by Decrease of BAFFR

Jan Krejseka, Martina Koláčkováa, Irena Lindrováb, Radovan Slezákb, Ctirad Andrýsa

aCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Clinical Immunology and Allergology, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Stomatology, Czech Republic

Received January 22, 2015
Accepted April 1, 2015

References

1. Bowman S, Barone F. Biologic treatments in Sjögren’s syndrome. Presse Med 2012; 41: e495–e509. <https://doi.org/10.1016/j.lpm.2012.05.024>
2. Brkic Z, Maria NI, van Helden-Meeuwsen CG et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013; 72(5): 728–735. <https://doi.org/10.1136/annrheumdis-2012-201381> <PubMed>
3. Cornec D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sjögren’s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 2012; 39(3): 161–167. <https://doi.org/10.1016/j.jaut.2012.05.014>
4. Daridon C, Devauchelle V, Hutin P et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum 2007; 56(4): 1134–1144. <https://doi.org/10.1002/art.22458>
5. Gardam S, Brink R. Non-canonical NF-κB signaling initiated by BAFF influences B cell biology at multiple junctures. Front Immunol 2014; 4(509): eCollection 2014.
6. Gottenberg JE, Cagnard N, Lucchesi C et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA 2006; 103(8): 2770–2775. <https://doi.org/10.1073/pnas.0510837103> <PubMed>
7. Groom J, Mackay F. B cells flying solo. Immunol Cell Biol 2008; 86(1): 40–46. <https://doi.org/10.1038/sj.icb.7100142>
8. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol 2008; 67(2): 185–192. <https://doi.org/10.1111/j.1365-3083.2007.02049.x>
9. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190 (11): 1697–1710. <https://doi.org/10.1084/jem.190.11.1697> <PubMed>
10. Moutsopoulos HM. Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994; 72(2): 162–165. <https://doi.org/10.1006/clin.1994.1123>
11. Nikolov NP, Illei GG. Pathogenesis of Sjögren’s syndrome. Curr Opin Rheumatol 2009; 21(5): 465–470. <https://doi.org/10.1097/BOR.0b013e32832eba21> <PubMed>
12. Pers JO, Youinou P. Are the B cells cast with the leading part in the Sjögren’s syndrome scenario? Oral Dis 2014; 20(6): 529–537; doi: 10.1111/odi.12153. <https://doi.org/10.1111/odi.12153>
13. Pollard RPE, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren’s syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013; 72(1): 146–148. <https://doi.org/10.1136/annrheumdis-2012-202071>
14. Quartuccio L, Salvin S, Fabris M et al. BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013; 52(2): 276–281. <https://doi.org/10.1093/rheumatology/kes180>
15. Sellam J, Miceli-Richard C, Gottenberg JE et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren’s syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007; 66(6): 790–797. <https://doi.org/10.1136/ard.2006.065656> <PubMed>
16. Schenider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189(11): 1747–1756. <https://doi.org/10.1084/jem.189.11.1747> <PubMed>
17. Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B-cell tolerance breakdown in Sjögren’s syndrome: focus on BAFF. Autoimmun Rev 2010; 9(9): 604–608. <https://doi.org/10.1016/j.autrev.2010.05.006>
18. Vincent FB, Sulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24(3): 203–215. <https://doi.org/10.1016/j.cytogfr.2013.04.003> <PubMed>
19. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren’s syndrome. A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61(6): 554–558. <https://doi.org/10.1136/ard.61.6.554> <PubMed>
20. Voulgarelis M, Tzioufas AG. Current aspects of pathogenesis in Sjögren’s syndrome. Ther Adv Musculoskelet Dis 2010; 2(6): 325–334. <https://doi.org/10.1177/1759720X10381431> <PubMed>
21. Ye Q, Wang L, Wells AD et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004; 34(10): 2750–2759. <https://doi.org/10.1002/eji.200425198>
22. Yoshimoto K, Tanaka M, Kojima M et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren’s syndrome. Arthritis Res Ther 2011; 13(5): R170. <https://doi.org/10.1186/ar3493> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive